Skip to main content

Insulin lispro

06-15-2022 | Insulin | News

Liver-targeted insulin reduces hypoglycemic events

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

06-05-2022 | ADA 2022 | Conference coverage | News

​​​​​​​Ultra-rapid lispro noninferior to standard version in children

Ultra-rapid lispro gives equivalent overall glycemic control to standard lispro, and is significantly better for some postprandial measurements in children with type 1 diabetes, shows the PRONTO-Peds trial.

07-23-2020 | Insulin lispro | News

PRONTO-T2D: ‘Good glycemic control’ with ultra-rapid insulin lispro

People with type 2 diabetes who use ultra-rapid insulin lispro as part of a basal–bolus regimen achieve similar overall glycemic control and better control of postprandial glucose excursions compared with those using standard lispro, report the PRONTO-T2D investigators.